Literature DB >> 19757204

Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy.

Guibo Feng1, Fei Xiao, Yang Lu, Zuchun Huang, Jie Yuan, Zheng Xiao, Zhiqin Xi, Xuefeng Wang.   

Abstract

Synaptic vesicle protein 2A (SV2A) involvement has been reported in the animal models of epilepsy. The aim of this study was to investigate the expression of SV2A in human intractable epilepsy (IE) brain tissue. Using immunohistochemistry, immunofluorescence, and Western blot, we detected SV2A expression in tissue samples from the anterior temporal neocortex of 33 patients who had been surgically treated for IE. We compared these tissues with nine histologically normal anterior temporal lobe samples from controls. SV2A immunoreactive staining was 0.1651+/-0.0564 in patient group and 0.2347+/-0.0187 in the control group (p<0.05) using immunohistochemistry, and this finding was consistently observed with Western blot analysis (0.1727 +/- 0.0471 versus 0.3976+/-0.0983, p<0.05). Immunofluorescence staining showed that SV2A was mainly accumulated in neurons. Our findings demonstrate that down-regulation of SV2A is present in patients with temporal lobe epilepsy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19757204     DOI： 10.1007/s12031-009-9288-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  19 in total

Review 1.  Mechanisms of antiepileptic drug resistance.

Authors:  Sanjay M Sisodiya
Journal:  Curr Opin Neurol       Date:  2003-04       Impact factor: 5.710

Review 2.  The evaluation and treatment of seizures.

Authors:  M L Scheuer; T A Pedley
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

3.  SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family.

Authors:  R Janz; T C Südhof
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

4.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).

Authors:  K M Crowder; J M Gunther; T A Jones; B D Hale; H Z Zhang; M R Peterson; R H Scheller; C Chavkin; S M Bajjalieh
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 5.  Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsia       Date:  2005-06       Impact factor: 5.864

6.  Differential expression of synaptic vesicle protein 2 (SV2) isoforms.

Authors:  S M Bajjalieh; G D Frantz; J M Weimann; S K McConnell; R H Scheller
Journal:  J Neurosci       Date:  1994-09       Impact factor: 6.167

7.  Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.

Authors:  Sjoukje T Toering; Karin Boer; Marjolein de Groot; Dirk Troost; Jan J Heimans; Wim G M Spliet; Peter C van Rijen; Floor E Jansen; Jan A Gorter; Jaap C Reijneveld; Eleonora Aronica
Journal:  Epilepsia       Date:  2009-02-12       Impact factor: 5.864

8.  Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.

Authors:  Michel Gillard; Pierre Chatelain; Bruno Fuks
Journal:  Eur J Pharmacol       Date:  2006-03-10       Impact factor: 4.432

9.  Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.

Authors:  Erwin A van Vliet; Eleonora Aronica; Sandra Redeker; Karin Boer; Jan A Gorter
Journal:  Epilepsia       Date:  2008-08-19       Impact factor: 5.864

10.  Altered expression of synaptotagmin I in temporal lobe tissue of patients with refractory epilepsy.

Authors:  Zheng Xiao; Yun Gong; Xue-Feng Wang; Fei Xiao; Zhi-Qin Xi; Yang Lu; Hong-Bin Sun
Journal:  J Mol Neurosci       Date:  2008-09-09       Impact factor: 3.444
View more
  27 in total

Review 1.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A).

Authors:  Songye Li; Zhengxin Cai; Wenjie Zhang; Daniel Holden; Shu-Fei Lin; Sjoerd J Finnema; Anupama Shirali; Jim Ropchan; Stephane Carre; Joel Mercier; Richard E Carson; Nabeel Nabulsi; Yiyun Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-07       Impact factor: 9.236

3.  Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue.

Authors:  Michel Koole; June van Aalst; Martijn Devrome; Nathalie Mertens; Kim Serdons; Brigitte Lacroix; Joel Mercier; David Sciberras; Paul Maguire; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-18       Impact factor: 9.236

4.  SV2 acts via presynaptic calcium to regulate neurotransmitter release.

Authors:  Qun-Fang Wan; Zhen-Yu Zhou; Pratima Thakur; Alejandro Vila; David M Sherry; Roger Janz; Ruth Heidelberger
Journal:  Neuron       Date:  2010-06-24       Impact factor: 17.173

5.  Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.

Authors:  Jing Shi; Feng Zhou; Li-Kun Wang; Guo-Feng Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

6.  Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.

Authors:  Amy R Dunn; Carlie A Hoffman; Kristen A Stout; Minagi Ozawa; Rohan K Dhamsania; Gary W Miller
Journal:  Brain Res       Date:  2017-12-21       Impact factor: 3.252

7.  Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue.

Authors:  Nathalie Mertens; Ralph Paul Maguire; Kim Serdons; Brigitte Lacroix; Joel Mercier; David Sciberras; Koen Van Laere; Michel Koole
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

8.  Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans.

Authors:  Sjoerd J Finnema; Nabeel B Nabulsi; Joël Mercier; Shu-Fei Lin; Ming-Kai Chen; David Matuskey; Jean-Dominique Gallezot; Shannan Henry; Jonas Hannestad; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-09       Impact factor: 6.200

Review 9.  PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.

Authors:  Zhengxin Cai; Songye Li; David Matuskey; Nabeel Nabulsi; Yiyun Huang
Journal:  Neurosci Lett       Date:  2018-07-31       Impact factor: 3.046

10.  Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.

Authors:  Itzel Jatziri Contreras-García; Gisela Gómez-Lira; Bryan Víctor Phillips-Farfán; Luz Adriana Pichardo-Macías; Mercedes Edna García-Cruz; Juan Luis Chávez-Pacheco; Julieta G Mendoza-Torreblanca
Journal:  Brain Sci       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.